ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN ADULTS >60 YEARS, IN COSTA RICAN SOCIAL SECURITY

被引：0
|
作者：
Chaverri, J. [1 ]
Castro, J. [2 ]
机构：
[1] Caja Costarricense Seguro Social, San Jose, C, Costa Rica
[2] Caja Costarricense Seguro Social, San Jose, SJ, Costa Rica
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN17
引用
收藏
页码：S171 / S171
页数：1
相关论文
共 50 条
  • [1] ECONOMIC IMPACT IN DOMINICAN REPUBLIC SENASA OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN OLDER ADULTS
    Del Villar-Tapia, Y.
    Brito-Tayson, G.
    Lizardo, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S173 - S173
  • [2] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    [J]. HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [3] A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Newall, A. T.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (04) : 818 - 825
  • [4] 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants
    Martinon-Torres, Federico
    Czajka, Hanna
    Center, Kimberly J.
    Wysocki, Jacek
    Majda-Stanislawska, Ewa
    Omenaca, Felix
    Bernaola Iturbe, Enrique
    Blazquez Gamero, Daniel
    Concheiro-Guisan, Ana
    Gimenez-Sanchez, Francisco
    Szenborn, Leszek
    Giardina, Peter C.
    Patterson, Scott
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    [J]. PEDIATRICS, 2015, 135 (04) : E876 - E886
  • [5] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    [J]. VACCINE, 2010, 28 (48) : 7634 - 7643
  • [6] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    [J]. VACCINE, 2015, 33 (38) : 4813 - 4819
  • [7] PUBLIC HEALTH AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN PUBLIC AND PRIVATE SYSTEM VERSUS PPSV23 AND NO VACCINATION IN OLDER ADULTS
    Ferreira, C. N.
    Santana, C. F.
    Rufino, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A839 - A839
  • [8] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
    Ansaldi, Filippo
    Pugh, Sarah
    Amicizia, Daniela
    Di Virgilio, Roberto
    Trucchi, Cecilia
    Orsi, Andrea
    Zollo, Alessandro
    Icardi, Giancarlo
    [J]. PATHOGENS, 2020, 9 (02):
  • [9] 13-Valent pneumococcal conjugate vaccine (PCV13) serotypes in adults with community acquired pneumonia in Taiwan
    Chang, S. C.
    Li, C. T.
    Cheng, S. L.
    Gray, S.
    Gonzalez, E.
    Pride, M.
    Sebastian, S.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 : S119 - S119
  • [10] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Beutels, P.
    McIntyre, P.
    Menzies, R.
    Reyes, J. F.
    Chen, C.
    Newall, A. T.
    [J]. VACCINE, 2017, 35 (34) : 4307 - 4314
12345